Market Overview:
The global premenstrual dysphoric disorder (PMDD) market is expected to register a CAGR of 7.5% during the forecast period, 2018-2030. The market growth can be attributed to the increasing prevalence of PMDD, rising awareness about PMDD and its symptoms, and growing demand for effective treatment options for PMDD. Based on type, the global premenstrual dysphoric disorder (PMDD) market is segmented into table product, inject product, and others. The table product segment is expected to account for a major share of the global PMDD market in 2018. This can be attributed to the high adoption rate of oral contraceptives as a treatment option for PMDD among women worldwide. However, the inject product segment is projected to grow at a higher CAGR during the forecast period owing to increasing preference for long-acting reversible contraception methods over other types of contraception methods among women globally. Based on application, the global premenstrual dysphoric disorder (PMDD) market is divided into hospital setting, clinic setting and others segments. The hospital setting segment accounted for majority share of revenue generated by application segments in 2017 and this trend is anticipated continue throughout forecast period owing high adoption rate os hormonal therapies as first line treatmentsfor severe casesof pmdd in hospitals settings across globe .
 Industry Outlook.svg)
Product Definition:
Premenstrual dysphoric disorder (PMDD) is a mood disorder linked to the menstrual cycle. Symptoms include severe mood swings, irritability, fatigue, bloating, and breast tenderness. These symptoms occur in the days leading up to menstruation and disappear once bleeding begins. PMDD is estimated to affect 3%–8% of women of reproductive age. It can interfere with work or school, relationships, and daily activities.
Table Product:
Table Product, it's usage.
Premenstrual dysphoric disorder is a type of premenstrual syndrome. It is characterized by symptoms such as mood swings, irritability, depression, anxiety and other physical symptoms such as breast tenderness & swelling.
Inject Product:
Injectable products are used to treat premenstrual dysphoric disorder, also known as PMDD. This is a type of depression that occurs in the weeks leading up to your period. It can be treated with an oral medication called fluoxetine (Prozac), which is generally prescribed along with another treatment plan for PMDD that may include therapy and lifestyle changes.
Application Insights:
Premenstrual dysphoric disorder finds application in various fields including hospital, clinic and others. In 2017, the hospital segment dominated the market with a share of over 60.0% in North America and Europe. This is due to factors such as high prevalence of PMDD among hospitalized patients as compared to the general population and availability of treatment options only for PMDD at that time.
The others segment includes home healthcare management, which has been witnessing significant growth owing to rising awareness about menopause symptoms along with an increase in health care facilities managing their own chronic conditions without consulting medical specialists first thing every morning by using smartphone applications or online portals (Menopause Management). These factors are anticipated to drive overall demand for Premenstrual Dysphoric Disorder¢â‚¬â„¢s treatment during the forecast period.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of manufacturers and suppliers, availability of effective treatment options, rising awareness about Premenstrual Syndrome (PMS) and its associated symptoms such as mood swings, abdominal cramps, diarrhea etc., are some factors attributing to the largest share. In addition, increasing research & development activities for commercialization of novel products is also expected to drive this regional market over the forecast period.
Asia Pacific is expected to grow at a lucrative rate during the forecast period owing to increasing awareness about PMDD among people especially women coupled with growing disposable income in emerging countries such as China and India.
Growth Factors:
- Increasing awareness about PMDD and its symptoms: There is a growing awareness about PMDD among people, especially women. This is helping to create a larger pool of potential patients for the treatment of PMDD.
- Growing number of research studies on PMDD: There has been an increase in the number of research studies being conducted on PMDD in recent years. This is helping to generate more interest in the disorder and also help identify new treatment options for it.
- Availability of effective treatments for PMDD: There are now a number of effective treatments available for managing the symptoms of PMDD, which is encouraging more people to seek help for this condition.
- Rising incidence rate of PMDD: The incidence rateof Premenstrual Dysphoric Disorder is rising globally, making it an important areaof focusfor healthcare providers and pharmaceutical companies alike .This provides opportunitiesfor growthin thePMDDisorder market . 5
Scope Of The Report
Report Attributes
Report Details
Report Title
Premenstrual Dysphoric Disorder (PMDD) Market Research Report
By Type
Table Product, Inject Product, Others
By Application
Hospital, Clinic, Others
By Companies
Teva, Eli Liliy, Pfizer, Bayer, GSK, Apotex, Bristol Laboratories, Mylan, Allergan
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
190
Number of Tables & Figures
133
Customization Available
Yes, the report can be customized as per your need.
Global Premenstrual Dysphoric Disorder (PMDD) Market Report Segments:
The global Premenstrual Dysphoric Disorder (PMDD) market is segmented on the basis of:
Types
Table Product, Inject Product, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Teva
- Eli Liliy
- Pfizer
- Bayer
- GSK
- Apotex
- Bristol Laboratories
- Mylan
- Allergan
 Market Overview.svg)
Highlights of The Premenstrual Dysphoric Disorder (PMDD) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Table Product
- Inject Product
- Others
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Premenstrual Dysphoric Disorder (PMDD) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Premenstrual dysphoric disorder (PMDD) is a mental health condition that affects women during the days leading up to their periods. Symptoms can include mood swings, anxiety, and depression. PMDD is thought to be caused by changes in the hormone estrogen levels.
Some of the major players in the premenstrual dysphoric disorder (pmdd) market are Teva, Eli Liliy, Pfizer, Bayer, GSK, Apotex, Bristol Laboratories, Mylan, Allergan.
The premenstrual dysphoric disorder (pmdd) market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Premenstrual Dysphoric Disorder (PMDD) Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Premenstrual Dysphoric Disorder (PMDD) Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Premenstrual Dysphoric Disorder (PMDD) Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Premenstrual Dysphoric Disorder (PMDD) Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Premenstrual Dysphoric Disorder (PMDD) Market Size & Forecast, 2018-2028
4.5.1 Premenstrual Dysphoric Disorder (PMDD) Market Size and Y-o-Y Growth
4.5.2 Premenstrual Dysphoric Disorder (PMDD) Market Absolute $ Opportunity
Chapter 5 Global Premenstrual Dysphoric Disorder (PMDD) Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Premenstrual Dysphoric Disorder (PMDD) Market Size Forecast by Type
5.2.1 Table Product
5.2.2 Inject Product
5.2.3 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Premenstrual Dysphoric Disorder (PMDD) Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Premenstrual Dysphoric Disorder (PMDD) Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Premenstrual Dysphoric Disorder (PMDD) Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Premenstrual Dysphoric Disorder (PMDD) Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Premenstrual Dysphoric Disorder (PMDD) Analysis and Forecast
9.1 Introduction
9.2 North America Premenstrual Dysphoric Disorder (PMDD) Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Premenstrual Dysphoric Disorder (PMDD) Market Size Forecast by Type
9.6.1 Table Product
9.6.2 Inject Product
9.6.3 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Premenstrual Dysphoric Disorder (PMDD) Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Premenstrual Dysphoric Disorder (PMDD) Analysis and Forecast
10.1 Introduction
10.2 Europe Premenstrual Dysphoric Disorder (PMDD) Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Premenstrual Dysphoric Disorder (PMDD) Market Size Forecast by Type
10.6.1 Table Product
10.6.2 Inject Product
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Premenstrual Dysphoric Disorder (PMDD) Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Premenstrual Dysphoric Disorder (PMDD) Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Premenstrual Dysphoric Disorder (PMDD) Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Premenstrual Dysphoric Disorder (PMDD) Market Size Forecast by Type
11.6.1 Table Product
11.6.2 Inject Product
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Premenstrual Dysphoric Disorder (PMDD) Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Premenstrual Dysphoric Disorder (PMDD) Analysis and Forecast
12.1 Introduction
12.2 Latin America Premenstrual Dysphoric Disorder (PMDD) Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Premenstrual Dysphoric Disorder (PMDD) Market Size Forecast by Type
12.6.1 Table Product
12.6.2 Inject Product
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Premenstrual Dysphoric Disorder (PMDD) Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Premenstrual Dysphoric Disorder (PMDD) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Premenstrual Dysphoric Disorder (PMDD) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Premenstrual Dysphoric Disorder (PMDD) Market Size Forecast by Type
13.6.1 Table Product
13.6.2 Inject Product
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Premenstrual Dysphoric Disorder (PMDD) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Premenstrual Dysphoric Disorder (PMDD) Market: Competitive Dashboard
14.2 Global Premenstrual Dysphoric Disorder (PMDD) Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Teva
14.3.2 Eli Liliy
14.3.3 Pfizer
14.3.4 Bayer
14.3.5 GSK
14.3.6 Apotex
14.3.7 Bristol Laboratories
14.3.8 Mylan
14.3.9 Allergan
